Tabrecta tablets 150mg, containing Capmatinib hydrochloride hydrate, are manufactured by Novartis Pharma. This medication (YJ code: 4291067F1023, 150mg 1 tablet) is a kinase inhibitor typically used to treat adult patients with metastatic non-small cell lung cancer (NSCLC) exhibiting MET exon 14 skipping.
Tabrecta tablets 150mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →